Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
NCT02465502
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
59
Enrollment
INDUSTRY
Sponsor class
Conditions
Colorectal Neoplasms
Interventions
DRUG:
Regorafenib (Stivarga, BAY73-4506)
Sponsor
Bayer